How the Pathological Microenvironment Affects the Behavior of Mesenchymal Stem Cells in the Idiopathic Pulmonary Fibrosis
Abstract
:1. Introduction
2. Results
2.1. MSCs Isolation and Characterization from Healthy and Fibrotic Lung
2.2. α-SMA, Collagen Type 1, Fibronectin, and TGF-β1 Expression
2.3. Cell Proliferation: Differences between Mock and Co-Cultured Cells
2.4. C-MSCs vs. IPF-MSCs: Expression of Genes Related to Inflammation
2.5. Expression of Genes Related to Inflammation after Co-Cultures
2.6. C-MSCs vs. IPF-MSCs: Cytokines Secretion
2.7. Cytokines Secretion after Co-Cultures
3. Discussion
4. Material and Methods
4.1. Patients Enrollment
4.2. Isolation and Characterization of Mesenchymal Stem Cells from Healthy and Fibrotic Lung
4.3. Production of α-SMA, Collagen Type 1, Fibronectin, and TGF-β1
4.4. NHLF Culture
4.5. MSCs Co-Cultures
4.6. Expression of Genes Related to Inflammation, Oxidative Stress, Hypoxya, and ECM Pathway
4.7. ELISA of Inflammation-Related Cytokines
4.8. Statistical Analysis
Author Contributions
Funding
Conflicts of Interest
References
- Liu, Y.M.; Nepali, K.; Liou, J.P. Idiopathic pulmonary fibrosis: Current status, recent progress, and emerging targets. J. Med. Chem. 2017, 60, 527–553. [Google Scholar] [CrossRef]
- Padilla, M. Idiopathic pulmonary fibrosis: The role of pathobiology in making a definitive diagnosis. Am. J. Manag. Care 2015, 21, s276–s283. [Google Scholar]
- King, T.E., Jr.; Tooze, J.A.; Schwarz, M.I.; Brown, K.R.; Cherniack, R.M. Predicting survival in idiopathic pulmonary fibrosis: Scoring system and survival model. Am. J. Respir. Crit. Care Med. 2001, 164, 1171–1181. [Google Scholar] [CrossRef]
- Tian, Y.; Li, H.; Gao, Y.; Liu, C.; Qiu, T.; Wu, H.; Cao, M.; Zhang, Y.; Ding, H.; Chen, J.; et al. Quantitative proteomic characterization of lung tissue in idiopathic pulmonary fibrosis. Clin. Proteom. 2019, 16, 1–11. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Steele, M.P.; Schwartz, D.A. Molecular mechanisms in progressive idiopathic pulmonary fibrosis. Annu. Rev. Med. 2013, 64, 265–276. [Google Scholar] [CrossRef] [PubMed]
- Desai, O.; Winkler, J.; Minasyan, M.; Herzog, E.L. The role of immune and inflammatory cells in idiopathic pulmonary fibrosis. Front. Med. 2018, 5, 43. [Google Scholar] [CrossRef] [PubMed]
- Blackwell, T.S.; Tager, A.M.; Borok, Z.; Moore, B.B.; Schwartz, D.A.; Anstrom, K.J. Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report. Am. J. Respir. Crit. Care. Med. 2014, 189, 214–222. [Google Scholar] [CrossRef] [PubMed]
- Bringardner, B.D.; Baran, C.P.; Eubank, T.D.; Marsh, C.B. The role of inflammation in the pathogenesis of idiopathic pulmonary fibrosis. Antioxid. Redox Signal. 2008, 10, 287–301. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Biswas, S.K. Does the Interdependence between Oxidative Stress and Inflammation Explain the Antioxidant Paradox? Oxid. Med. Cell Longev. 2016, 2016, 5698931. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bartels, K.; Grenz, A.; Eltzschig, H.K.P. Hypoxia and inflammation are two sides of the same coin. Proc. Natl. Acad. Sci. USA 2013, 110, 18351–18352. [Google Scholar] [CrossRef] [Green Version]
- Senavirathna, L.K.; Huang, C.; Yang, X.; Munteanu, M.C.; Sathiaseelan, R.; Xu, D.; Henke, C.A.; Liu, L. Hypoxia induces pulmonary fibroblast proliferation through NFAT signaling. Sci. Rep. 2018, 8, 2709. [Google Scholar] [CrossRef]
- Cheresh, P.; Kim, S.J.; Tulasiram, S.; Kamp, D.W. Oxidative stress and pulmonary fibrosis. Biochim. Biophys. Acta 2013, 1832, 1028–1040. [Google Scholar] [CrossRef] [Green Version]
- Bernardo, M.E.; Fibbe, W.E. Mesenchymal stromal cells: Sensors and switchers of inflammation. Cell Stem. Cell 2013, 13, 392–402. [Google Scholar] [CrossRef] [Green Version]
- Campanati, A.; Orciani, M.; Sorgentoni, G.; Consales, V.; Offidani, A.; Di Primio, R. Pathogenetic characteristics of mesenchymal stem cells in hidradenitis suppurativa. JAMA Dermatol. 2018, 154, 1184–1190. [Google Scholar] [CrossRef]
- Orciani, M.; Caffarini, M.; Lazzarini, R.; Delli Carpini, G.; Tsiroglou, D.; Di Primio, R.; Ciavattini, A. Mesenchymal Stem Cells from Cervix and Age: New Insights into CIN Regression Rate. Oxid. Med. Cell. Longev. 2018, 2018, 1545784. [Google Scholar] [CrossRef] [Green Version]
- Martin, A.; Jahn, A.; Rio Bocos, C.; Montes, A.; Pons, P.J.; Mercader, J.; Velasco, J.; Gómez, C.; Villena, C.; Carvajal, Á.F.; et al. Characterization of Mesenchymal Stem Cells obtained from human lungs with and without Idiopathic Pulmonary Fibrosis. Eur. J. Respir. 2020, 6, 103. [Google Scholar]
- Hostettler, K.E.; Gazdhar, A.; Khan, P.; Savic, S.; Tamo, L.; Lardinois, D. Multipotent mesenchymal stem cells in lung fibrosis. PLoS ONE 2017, 12, e0181946. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Li, X.; Yue, S.; Luo, Z. Mesenchymal stem cells in idiopathic pulmonary fibrosis. Oncotarget 2017, 8, 102600. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Toonkel, R.L.; Hare, J.M.; Matthay, M.A.; Glassberg, M.K. Mesenchymal stem cells and idiopathic pulmonary fibrosis. Potential for clinical testing. Am. J. Respir. Crit. Care. Med. 2013, 188, 133–140. [Google Scholar] [CrossRef]
- Dominici, M.; Le Blanc, K.; Mueller, I.; Slaper-Cortenbach, I.; Marini, F.C.; Krause, D.S. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8, 315–317. [Google Scholar] [CrossRef] [PubMed]
- Orciani, M.; Caffarini, M.; Biagini, A.; Lucarini, G.; Delli Carpini, G.; Berretta, A. Chronic inflammation may enhance leiomyoma development by the involvement of progenitor cells. Stem. Cells Int. 2018, 2018, 1716246. [Google Scholar] [CrossRef] [PubMed]
- Rueden, C.T.; Schindelin, J.; Hiner, M.C.; DeZonia, B.E.; Walter, A.E.; Arena, E.T.; Eliceiri, K.W. ImageJ2: ImageJ for the next generation of scientific image data. BMC Bioinform. 2017, 18, 529. [Google Scholar] [CrossRef] [PubMed]
- Kashyap, V.; Rezende, N.C.; Scotland, K.B.; Shaffer, S.M.; Persson, J.L.; Gudas, L.J.; Mongan, N.P. Regulation of stem cell pluripotency and differentiation involves a mutual regulatory circuit of the NANOG, OCT4, and SOX2 pluripotency transcription factors with polycomb repressive complexes and stem cell microRNAs. Stem. Cells Dev. 2009, 18, 1093–1108. [Google Scholar] [CrossRef]
- Lin, L.; Han, Q.; Xiong, Y.; Li, T.; Liu, Z.; Xu, H. Krüpple-like-factor 4 attenuates lung fibrosis via inhibiting epithelial-mesenchymal transition. Sci. Rep. 2017, 7, 1–12. [Google Scholar] [CrossRef]
- Jiang, Y.; Wells, A.; Sylakowski, K.; Clark, A.M.; Ma, B. Adult stem cell functioning in the tumor micro-environment. Int. J. Mol. Sci. 2019, 20, 2566. [Google Scholar] [CrossRef] [Green Version]
- Fernandez, I.E.; Eickelberg, O. The impact of TGF-β on lung fibrosis: From targeting to biomarkers. Proc. Am. Thorac. Soc. 2012, 9, 111–116. [Google Scholar] [CrossRef]
- Meyer, K.C.; Danoff, S.K.; Lancaster, L.H.; Nathan, S.D. Management of idiopathic pulmonary fibrosis in the elderly patient. Chest 2015, 148, 242–252. [Google Scholar] [CrossRef] [PubMed]
- Schafer, M.J.; White, T.A.; Iijima, K.; Haak, A.J.; Ligresti, G.; Atkinson, E.J. Cellular senescence mediates fibrotic pulmonary disease. Nat. Commun. 2017, 8, 1–11. [Google Scholar] [CrossRef]
- Schuliga, M.; Pechkovsky, D.V.; Read, J.; Waters, D.W.; Blokland, K.E.; Reid, A.T. Mitochondrial dysfunction contributes to the senescent phenotype of IPF lung fibroblasts. J. Cell. Mol. Med. 2018, 22, 5847–5861. [Google Scholar] [CrossRef]
- Blokland, K.E.; Waters, D.W.; Schuliga, M.; Read, J.; Pouwels, S.D.; Grainge, C.L. Senescence of IPF Lung Fibroblasts Disrupt Alveolar Epithelial Cell Proliferation and Promote Migration in Wound Healing. Phamaceutics 2020, 12, 389. [Google Scholar] [CrossRef]
- Raghu, G.; Anstrom, K.J.; King, T.E.; Lasky, J.A., Jr.; Martinez, F.J. Idiopathic Pulmonary Fibrosis Clinical Research Network. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N. Engl. J. Med. 2012, 366, 1968–1977. [Google Scholar] [PubMed]
- Heukels, P.; Moor, C.C.; von der Thüsen, J.H.; Wijsenbeek, M.S.; Kool, M. Inflammation and immunity in IPF pathogenesis and treatment. Respir. Med. 2019, 147, 79–91. [Google Scholar] [CrossRef]
- Contreras, R.A.; Figueroa, F.E.; Djouad, F.; Luz-Crawford, P. Mesenchymal stem cells regulate the innate and adaptive immune responses dampening arthritis progression. Stem. Cells Int. 2016, 2016, 3162743. [Google Scholar] [CrossRef]
- Saito, F.; Tasaka, S.; Inoue, K.; Miyamoto, K.; Nakano, Y.; Ogawa, Y. Role of interleukin-6 in bleomycin-induced lung inflammatory changes in mice. Am. J. Respir. Cell Mol. 2008, 38, 566–571. [Google Scholar] [CrossRef]
- Yang, L.; Herrera, J.; Gilbertsen, A.; Xia, H.; Smith, K.; Benyumov, A.; Bitterman, P.B.; Henke, C.A. IL-8 mediates idiopathic pulmonary fibrosis mesenchymal progenitor cell fibrogenicity. Am. J. Physiol. Lung Cell Mol. Physiol. 2018, 314, L127–L136. [Google Scholar] [CrossRef] [Green Version]
- Francisco-Cruz, A.; Aguilar-Santelises, M.; Ramos-Espinosa, O.; Mata-Espinosa, D.; Marquina-Castillo, B.; Barrios-Payan, J.; Hernandez-Pando, R. Granulocyte–macrophage colony-stimulating factor: Not just another haematopoietic growth factor. Med. Oncol. 2014, 31, 774. [Google Scholar] [CrossRef]
- Reynolds, H.Y. Lung inflammation and fibrosis: An alveolar macrophage-centered perspective from the 1970s to 1980s. Am. J. Respir. Crit. Care Med. 2005, 171, 98–102. [Google Scholar] [CrossRef] [PubMed]
- Goodwin, J.; Choi, H.; Hsieh, M.H.; Neugent, M.L.; Ahn, J.M.; Hayenga, H.N. Targeting hypoxia-inducible factor-1α/pyruvate dehydrogenase kinase 1 axis by dichloroacetate suppresses bleomycin-induced pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 2018, 58, 216–231. [Google Scholar] [CrossRef] [PubMed]
- Kikuchi, N.; Ishii, Y.; Morishima, Y.; Yageta, Y.; Haraguchi, N.; Itoh, K.; Yamamoto, M.; Hizawa, N. Nrf2 protects against pulmonary fibrosis by regulating the lung oxidant level and Th1/Th2 balance. Respir. Res. 2010, 11, 31. [Google Scholar] [CrossRef] [Green Version]
- Lee, E.J.; Cárdenes, N.; Álvarez, D.; Sellarés, J.; Sembrat, J.; Aranda, P.; Peng, Y.; Bullock, J.; Nouraie, S.M.; Mora, A.L.; et al. Mesenchymal stem cells reduce ER stress via PERK-Nrf2 pathway in an aged mouse model. Respirology 2020, 25, 417–426. [Google Scholar] [CrossRef]
- Kliment, C.R.; Oury, T.D. Oxidative stress, extracellular matrix targets, and idiopathic pulmonary fibrosis. Free Radic. Biol. Med. 2010, 49, 707–717. [Google Scholar] [CrossRef] [PubMed]
- Raghu, G.; Remy-Jardin, M.; Myers, J.L.; Richeldi, L.; Ryerson, C.J.; Lederer, D.J. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am. J. Respir. Crit. Care Med. 2018, 198, e44–e68. [Google Scholar] [CrossRef] [PubMed]
- Colella, S.; Haentschel, M.; Shah, P.; Poletti, V.; Hetzel, J. Transbronchial lung cryobiopsy in interstitial lung diseases: Best practice. Respiration 2018, 95, 383–391. [Google Scholar] [CrossRef]
- Campanati, A.; Orciani, M.; Sorgentoni, G.; Consales, V.; Mattioli Belmonte, M.; Di Primio, R.; Offidani, A. Indirect co-cultures of healthy mesenchymal stem cells restore the physiological phenotypical profile of psoriatic mesenchymal stem cells. Clin. Exp. Immunol. 2018, 193, 234–240. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lazzarini, R.; Olivieri, F.; Ferretti, C.; Mattioli-Belmonte, M.; Di Primio, R.; Orciani, M. mRNAs and miRNAs profiling of mesenchymal stem cells derived from amniotic fluid and skin: The double face of the coin. Cell Tissue Res. 2014, 355, 121–130. [Google Scholar] [CrossRef]
- Campanati, A.; Orciani, M.; Lazzarini, R.; Ganzetti, G.; Consales, V.; Sorgentoni, G. TNF-α inhibitors reduce the pathological Th1–Th17/Th2 imbalance in cutaneous mesenchymal stem cells of psoriasis patients. Exp. Dermatol. 2017, 26, 319–324. [Google Scholar] [CrossRef]
C-MSCs | IPF-MSCs | |
---|---|---|
FIBRONECTIN % | 44.59 ± 9.596 | 89.98 ± 4.539 * |
COL1A1 % | 12.47 ± 2.529 | 77.19 ± 4.440 * |
α-SMA % | 16.09 ± 7.094 | 76.58 ± 4.690 * |
TGF-β % | 4.757 ± 0.793 | 32.73 ± 5.046 * |
Characteristics | IPF | CTRL |
---|---|---|
Age, years | 70.3 ± 6.4 | 61.7 ± 0.5 |
Sex, no. male/no. female | 1/2 | 0/3 |
Smoking status (no. Never/Ever) | 1/2 | 2/1 |
Pulmonary function test at baseline, % predicted | ||
FEV1 | 85.0 ± 31.0 | 89.5 ± 14 |
FVC | 83.3 ± 38.3 | 98.5 ± 19.5 |
DLco | 56.0 ± 4.0 | 68 ± 17 |
GENE | FORWARD 5′–3′ | REVERSE 5′–3′ |
---|---|---|
GAPDH | CCCTTCATTGACCTCAACTACATG | TGGGATTTCCATTGATGACAAGC |
SOX2 | ACACCAATCCCATCCACACT | GCAAACTTCCTGCAAAGCTC |
OCT4 | AGCGAACCAGTATCGAGAAC | TTACAGAACCACACTCGGAC |
NANOG | TGAACCTCAGCTACAAACAG | CTGGATGTTCTGGGTCTGGT |
KLF4 | CCCACACAGGTGAGAAACCT | ATGTGTAAGGCGAGGTGGTC |
HIF1A | GAAAGAGCCCGATGCCCT | TGATATGATCGTGTCCCCAGC |
NFKB | AATGGTGGAGTCTGGGAAGG | TCTGACGTTTCCTCTGCACT |
VEGF | CCTCCGAAACCATGAACTTT | ATGATTCTGCCCTCCTCCTTCT |
SOD2 | CTGGACAAACCTCAGCCCTAAC | AACCTGAGCCTTGGACACCAAC |
CAT | GTGCGGAGATTCAACACTGCCA | TTCTCACACACGCGGCAATG |
GPX | GTGCTCGGCTTCCCGTGCAAC | CTCGAAGAGCATGAAGTTGGGC |
GR | TATGTGAGCCGCCTGAATGCCA | CACTGACCTCTATTGTGGGCTTG |
NRF2 | CAGCGACGGAAAGAGTATGA | TGGGCAACCTGGGAGTAG |
IL1A | TCATTGGCGTTTGAGTCAGC | ACCACCATGCTCTCCTTGAA |
IL1B | CGAATCTCCGACCACCACTA | AGCCTCGTTATCCCATGTGT |
IL4 | TTTGCTGCCTCCAAGAACAC | GTCGAGCCGTTTCAGGAATC |
IL6 | ATTCTGCGCAGCTTTAAGGA | AACAACAATCTGAGGTGCCC |
IL8 | GTGTGGGTCTGTTGTAGGGT | TCGGATATTCTCTTGGCCCT |
IL12 | AATGTTCCCATGCCTTCACC | CCAATGGTAAACAGGCCTCC |
TNF-α | CGAGTCTGGGCAGGTCTACTTT | AAGCTGTAGGCCCCAGTGAGTT |
G-CSF | GGACATGGTTTGACTCCCGA | CTTCCTTTCACACACAGGCC |
TGF-β1 | CAAGTGGACATCAACGGGTTC | TGCGGAAGTCAATGTAGC |
COL1A1 | GAGGGCCAAGACGACGAAGACATC | CAGATCACGTCATCGCACAAC |
α-SMA | AGCCAAGCACTGTCAGGAATC | AGCCATTGTCACACACCAAGG |
FN1 | CGGGAGGCATTAGAAGGGAT | TTGCTTTGACTGACAGCCAC |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Bonifazi, M.; Di Vincenzo, M.; Caffarini, M.; Mei, F.; Salati, M.; Zuccatosta, L.; Refai, M.; Mattioli-Belmonte, M.; Gasparini, S.; Orciani, M. How the Pathological Microenvironment Affects the Behavior of Mesenchymal Stem Cells in the Idiopathic Pulmonary Fibrosis. Int. J. Mol. Sci. 2020, 21, 8140. https://doi.org/10.3390/ijms21218140
Bonifazi M, Di Vincenzo M, Caffarini M, Mei F, Salati M, Zuccatosta L, Refai M, Mattioli-Belmonte M, Gasparini S, Orciani M. How the Pathological Microenvironment Affects the Behavior of Mesenchymal Stem Cells in the Idiopathic Pulmonary Fibrosis. International Journal of Molecular Sciences. 2020; 21(21):8140. https://doi.org/10.3390/ijms21218140
Chicago/Turabian StyleBonifazi, Martina, Mariangela Di Vincenzo, Miriam Caffarini, Federico Mei, Michele Salati, Lina Zuccatosta, Majed Refai, Monica Mattioli-Belmonte, Stefano Gasparini, and Monia Orciani. 2020. "How the Pathological Microenvironment Affects the Behavior of Mesenchymal Stem Cells in the Idiopathic Pulmonary Fibrosis" International Journal of Molecular Sciences 21, no. 21: 8140. https://doi.org/10.3390/ijms21218140